Dr. Tarek Alam, who has participated in interviews with TrialSite News in the past, along with a sizeable research team from the Bangladesh Medical College and the Shomman Foundation had their COVID-19 research involving what Dr. Alam terms “the people’s medicine” published in the peer review European Journal of Medical & Health Sciences (EJMED) recently. Although multiple vaccines are under development, and a few in the East have been rushed through to emergency approval while in the West the Pfizer/BioNTech candidate is now authorized for emergency use (with Moderna soon to follow), the needs and demands for an a U.S. Food and Drug Administration (FDA) approved product rises to help protect billions worldwide from this most devastating of pandemics. Important observational research led by Alam, a dedicated physician and researcher to those most in need in Bangladesh, sought out to determine the effectiveness of Ivermectin when administered as pre-exposure prophylaxis for COVID-19. The results were notable, perhaps even compelling. Out of 60 subjects in the control group, 44 (73.3%) were positive for COVID-19 while only 4 out of 58 (6.9%) of the experimental group ultimately succumbed to a SARS-CoV-2 infection, the virus behind COVID-19. Albeit not a randomized controlled study, these findings are but one of a growing many associated with case series, observational and a few randomized controlled studies pointing to material evidence that Ivermectin does serve to inhibit and perhaps even block COVID-19. Of course, more research is required: TrialSite has evangelized for the National Institutes of Health (NIH) to invest in a study.
The medical establishments worldwide are not taking Ivermectin too seriously. That is unfortunate. As TrialSite recently covered the FLCCC press conference live in Houston, the numbers of visitors to TrialSite articles and YouTube content has exploded. There is a growing interest among a wide swathe of the population to at least learn more. But at the same time, federal research and health agencies have used over $12.5 billion in taxpayer money targeting vaccines and advanced novel monoclonal antibodies. The plea isn’t to stop funding pharma initiatives but rather simply to add to the portfolio of research targets.
The Latest Bangladesh Medical College Study
In this study, which TrialSite covered prior, the investigators treated 118 healthcare providers enrolled in a leading Dhaka tertiary hospital and was segmented into a control group and experimental group. While the experimental group took an oral monthly dose of Ivermectin (12mg) for 4 months both groups were exposed, as health care workers, to COVID-19 positive patients being admitted into this hospital during the ongoing study period.
The team’s results were compelling: 73% of those health care workers placed in the control group ended up getting infected with COVID-19 while only 6.9% of the group taking Ivermectin ended up with an infection (p-value <0.05).
Dr. Alam and team concluded that this already FDA-approved drug, used by many millions of people in primarily the tropical world to combat parasites, should be subject to large-scale clinical trials worldwide to ascertain its effectiveness as pre-exposure prophylaxis for COVID-19.
This study represents yet another Ivermectin-based study addressing COVID-19 that has been accepted to a prestigious peer-review medical journal. In the case of EJMED, the internally focused journal publishes bimonthly full-length, state-of-the-art research papers, reviews, case studies related to all areas of medical and health sciences.
TrialSite & Dr. Alam’s Work
For more references to a number of articles and interviews involving Dr. Tarek Alam in Bangladesh, see our July 29 piece showcasing an interview with the Dhaka-based physician/researcher showcasing how Ivermectin worked overwhelmingly well on over 400 patients. Dr. Alam successfully treated another 100 patients, which was reported in the Journal of Bangladesh College of Physicians and Surgeons.
Call to Action: TrialSite suggests that the development of a range of therapies and approaches to battle COVID-19 are important. Obviously, vaccines are critical as are the continued investigation into sophisticated monoclonal antibodies from companies such as Regeneron, Lilly and AstraZeneca. Just as important are exploration into other therapies, especially existing approved repurposed drugs, such as Ivermectin, that if safe and effective, can help provide the world more choice—an important element in market systems.